Stockreport

ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma [Yahoo! Finance]

Arcellx, Inc.  (ACLX) 
PDF response rate and a 76% complete response rate, with 56% of patients remaining progression-free after 24 months. These results are comparable to those of existing treatm [Read more]